Product Overview
Composition
1 amp. contains glycosaminoglycan-peptide complex 1 ml
pharmachologic effect
A drug that regulates metabolism in cartilage tissue
Indications
Degenerative-dystrophic diseases of the joints:
- gonarthrosis;
- arthrosis of the interdigital joints;
- coxarthrosis;
- spondylosis;
- spondyloarthrosis;
- meniscopathy;
- chondromalacia of the patella.
Contraindications
- hypersensitivity to drug components;
- rheumatoid arthritis;
- age under 18;
- pregnancy;
- period of breastfeeding;
- use in women of reproductive age who do not follow reliable methods of contraception.
Side effects
Determination of the frequency of adverse reactions (according to the WHO classification): very often (≥1 / 10), often (from ≥1 / 100 to <1/10), infrequently (from ≥1 / 1000 to <1/100), rarely (from ≥1 / 10,000 to <1/1000), very rare (<1/10 000), the frequency is unknown (it was not possible to establish the frequency of occurrence based on the available data) .
From the immune system: rarely - allergic reactions, incl. anaphylactoid reactions, anaphylactic shock.
If these or any other side effects appear, the patient should stop using the drug and inform the attending physician about it.
Interaction
The drug Rumalon can be used simultaneously with NSAIDs and GCS.
With simultaneous use with indirect anticoagulants, antiplatelet agents and fibrinolytics, their effect may be enhanced.
How to take, course of administration and dosage
The drug is administered deeply intramuscularly: on the 1st day - 0.3 ml, on the 2nd day - 0.5 ml, and then 3 times a week, 1 ml for 5-6 weeks.
A second course of treatment - after consulting a doctor according to the same scheme.
Overdose
To date, no cases of overdose have been reported.
Special instructions
With simultaneous use with indirect anticoagulants, antiplatelet agents and fibrinolytics, frequent monitoring of blood coagulation parameters is necessary.
Influence on the ability to drive vehicles and mechanisms
The use of the drug does not affect the ability to perform potentially hazardous activities requiring increased concentration of attention and speed of psychomotor reactions (driving vehicles, working with moving mechanisms, the work of a dispatcher and an operator).
Release form
Solution for intramuscular administration from pale yellow with a brownish tinge to yellowish brown, transparent, with the smell of metacresol.
